Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 255 participants.

Also called NCT01932203

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01932203
Other papers using this trial's data
  • Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial Stroke, 2022-03 DOI, PubMed 34781708

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01932203. Randomized; quadruple masking; primary purpose treatment. Start 2013-07-17 (actual); primary completion 2019-08-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
Acronym
Challenge
Condition
Cerebral Small Vessel Disease
Intervention (Drug)
aspirin
Intervention (Drug)
cilostazol
Lead sponsor
Inha University Hospital (class: other)
Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01932203
Content hash
076ac43d0daa97a94d73db423cb2a6b4cc6930e9cca442fe25093d5da5d20f17